Sean Laaman
Stock Analyst at Morgan Stanley
(2.32)
# 2,304
Out of 4,944 analysts
7
Total ratings
50%
Success rate
12.55%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Overweight | $48 → $46 | $38.49 | +19.51% | 1 | Jul 29, 2025 | |
| AXSM Axsome Therapeutics | Assumes: Overweight | $190 | $109.39 | +73.69% | 1 | Jul 3, 2025 | |
| IRON Disc Medicine | Assumes: Overweight | $85 | $61.10 | +39.12% | 1 | Jul 3, 2025 | |
| CERT Certara | Assumes: Equal-Weight | $16 | $11.17 | +43.24% | 1 | Jul 3, 2025 | |
| ONC BeOne Medicines | Maintains: Overweight | $313 → $330 | $307.51 | +7.31% | 1 | Jun 27, 2025 | |
| ALEC Alector | Assumes: Underweight | $3 → $1.5 | $2.18 | -31.19% | 1 | Mar 7, 2025 | |
| RMD ResMed | Upgrades: Overweight | $169 | $288.28 | -41.38% | 1 | Oct 27, 2023 |
Exelixis
Jul 29, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $38.49
Upside: +19.51%
Axsome Therapeutics
Jul 3, 2025
Assumes: Overweight
Price Target: $190
Current: $109.39
Upside: +73.69%
Disc Medicine
Jul 3, 2025
Assumes: Overweight
Price Target: $85
Current: $61.10
Upside: +39.12%
Certara
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $16
Current: $11.17
Upside: +43.24%
BeOne Medicines
Jun 27, 2025
Maintains: Overweight
Price Target: $313 → $330
Current: $307.51
Upside: +7.31%
Alector
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $2.18
Upside: -31.19%
ResMed
Oct 27, 2023
Upgrades: Overweight
Price Target: $169
Current: $288.28
Upside: -41.38%